Ralph Boccia, MD
Hematology & Oncology · Bethesda, MDNPI 1881663284
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,067,020 of the $3,139,728 with a category attached, or 65.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 9.6%. Reporting peaked in 2019 at $707,458 and has fallen 65.5% since, to $244,074 in 2025. Among hematology & oncology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,283 payments — averaging $956.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$300K
- Johnson & Johnson$218K
- AbbVie$214K
- Bristol Myers Squibb$175K
- Amgen$166K
- AstraZeneca$163K
- plus $1.9M from 54 others
Across 1,287 payments — averaging $6990.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2M
- Takeda Pharmaceuticals U.S.A., Inc.$1000K
- AbbVie$860K
- Daiichi Sankyo Inc.$641K
- Incyte Corporation$614K
- Genentech, Inc.$590K
- plus $3.3M from 29 others
What the payments were for
- Consulting fees$771,59825%
- Speaking & faculty fees$2,067,02066%
- Travel & lodging$230,0677%
- Food & beverage$70,1992%
- Education$8440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$176,185
- Erleada$167,308
- LIBTAYO$163,924
- BRUKINSA$152,993
- OPDIVO$150,193
- Venclexta$132,704
- EPKINLY$114,018
- Tavalisse$101,091
- Monoferric$100,588
- FARYDAK$100,241
- INJECTAFER$92,758
- Pedmark$89,944
- Kyprolis$85,768
- SARCLISA$84,025
- FYARRO$83,452
- Inrebic$83,014
- XPOVIO$71,638
- COSELA$69,134
- Nplate$62,773
- Reblozyl$56,642
How this compares
$3,139,728 in reported general payments places this provider in the 95th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 81 | $1,429,136 |
| CalquenceAcalabrutinib Maleate | 55 | $805,780 |
| BrukinsaZanubrutinib | 50 | $759,453 |
| JakafiRuxolitinib Phosphate | 42 | $727,922 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $394,541 |
| PomalystPomalidomide | 17 | $344,488 |
| TasignaNilotinib Hcl | 12 | $241,710 |
| IbrancePalbociclib | 15 | $215,397 |
| ErleadaApalutamide | 14 | $197,309 |
| VenclextaVenetoclax | 11 | $169,356 |
| NinlaroIxazomib Citrate | 12 | $136,912 |
| SprycelDasatinib | 11 | $108,598 |
| DopteletAvatrombopag Maleate | 13 | $96,117 |
| EliquisApixaban | 107 | $80,810 |
| XareltoRivaroxaban | 61 | $64,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $175,064 | $1,429,13681 claims |
| AstraZenecaCalquence | $163,241 | $805,78055 claims |
| Beigene USA, Inc.Brukinsa | $139,519 | $759,45350 claims |
| Incyte CorporationJakafi | $109,249 | $727,92242 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $300,463 | $453,08628 claims |
| GSKOjjaara | $19,694 | $394,54114 claims |
| PfizerIbrance, Eliquis | $8,810 | $296,208122 claims |
| Johnson & JohnsonErleada, Xarelto | $218,434 | $262,12875 claims |
| NovartisTasigna | $5,739 | $241,71012 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro, Gammagard Liquid | $23,098 | $178,37525 claims |
| AbbVieVenclexta | $213,968 | $169,35611 claims |
| Dova PharmaceuticalsDoptelet | $54,384 | $96,11713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Bethesda
- Sandra SwainBethesda$1M
- Chitra RajagopalBethesda$89K
- Susan LeitmanBethesda$44K
- Giuseppe GiacconeBethesda$32K
- Phillip ScheinbergBethesda$27K
- Steven PavleticBethesda$13K
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.